Select publications

Baum M, O'Shaughnessy JA. Management of premenopausal women with early-stage breast cancer: is there a role for ovarian suppression? Clin Breast Cancer 2002;3(4):260-7. Abstract

de Haes H et al. Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group. J Clin Oncol 2003;21(24):4510-6. Abstract

Fogelman I et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). OsteoporosInt 2003;14(12):1001-6. Abstract

Forward DP et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004;90(3):590-4. Abstract

Jakesz R et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer — Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002;20(24):4621-7. Abstract

Jonat W et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research AssociationStudy. J Clin Oncol 2002;20(24):4628-35. Abstract

Kaufmann M et al. Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 2003;39(12):1711-7. Abstract

Kohli M et al. Combined endocrine blockade in premenopausal breast cancer: a superior therapeutic option for adjuvant management? J Clin Oncol 2003;21(12):2445. No abstract available.

Malayeri R. Can endocrine treatment for hormone-positive premenopausal women with early breast cancer replace adjuvant chemotherapy? J Clin Oncol 2003;21(12):2444-5. No abstract available.

Nystedt M et al. Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer--self-rated physiological effects and symptoms. Acta Oncol 2000;39(8):959-68. Abstract

Pater JL, Parulekar WR. Ovarian ablation as adjuvant therapy for premenopausal women with breast cancer--another step forward. J Natl CancerInst 2003;95(24):1811-2. No abstract available.

Robertson JF, Blamey RW. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women. Eur J Cancer 2003;39(7):861-9. Abstract

Sainsbury R. Ovarian ablation in the adjuvant treatment of premenopausal and perimenopausal breast cancer. Br J Surg 2003;90(5):517-26. Abstract